This discrepancy between the prior study and our study regarding the utility of EZH2 for distinguishing type B3 thymoma from thymic carcinoma highlights the value of independent validation of emerging markers prior to their routine clinical use, and the value of providing antibody clones in recommendations. This evidence concerns the gene EZH2 and thymoma.